ArticleClinical and experimental medicine2025
The association between 4-HPR-mediated LCN2 suppression and reduced intestinal cell senescence in ulcerative colitis.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Depleting luminal cysteine with engineered bacteroides vulgatus alleviates experimental colitis by suppressing Th17 differentiation through an ATF6-dependent mechanism.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Extracellular Vesicles Derived fromNanomaterials (Basel, Switzerland) · 2026Article
- The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ulcerative colitis is a type of inflammatory bowel disease that can significantly impact patients' life, leading to long-term complications. Cellular senescence plays a significant role in the occurrence and development of enteritis. The purpose of this study is to identify a specific drug and potential target that can inhibit intestinal cell senescence, thereby improving the clinical outcomes of enteritis. Bioinformatics analysis was used to identify the drug and target that associated with cellular senescence and ulcerative colitis. LPS-induced in vitro models and DSS-induced in vivo colitis models were used to confirm the association between colitis and aging, as well as the ability of the drug to alleviate colitis symptoms. Bioinformatics analysis suggested that Fenretinide (4-HPR) may influence the progression of ulcerative colitis by targeting LCN2 to modulate cellular senescence. Western blot analysis revealed high expression of LCN2 in patients with ulcerative colitis (p- value < 0.05). In the in vivo experiments utilizing a DSS-induced colitis model, 4-HPR was shown to be both safe and effective in inhibiting colitis progression. Western blot analysis indicated the downregulation of the senescence markers P16 and P21 following 4-HPR treatment (adjusted p-value < 0.0001). Moreover, β-galactosidase staining of intestinal tissues revealed a reduction in the accumulation of senescent cells in the 4-HPR-treated group compared to the DSS group (adjusted p-value < 0.0001). The potential mechanism might be related to the regulation of the Treg/Th17 balance. 4-HPR reduced the intestinal cell senescence by inhibiting the expression of LCN2 that alleviated the symptoms of ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.